Stimulants are the most effective medications for ADHD — by a substantial margin. The effect sizes in trials are larger than for almost any psychiatric intervention. For the patient with ADHD whose function is impaired, stimulants frequently restore the ability to work, study, and complete daily tasks in ways that nothing else reliably does.
- Class
- Central Nervous System Stimulants
- Mechanism
- Methylphenidate family: blocks DAT and NET (reuptake inhibition). Amphetamine family: blocks DAT/NET AND directly releases DA/NE from presynaptic vesicles. Both raise synaptic DA and NE in PFC and striatum.
- Typical dose
- Drug-specific
- Half-life
- Drug-specific (varies by formulation widely)
- FDA indications
- ADHD, narcolepsy. Off-label: treatment-resistant depression augmentation, cognitive enhancement in dementia/TBI (controversial).
- Key adverse effects
- Appetite suppression, weight loss, insomnia, headache, BP/HR elevation, anxiety/agitation, growth velocity slowing in children (catch-up usually occurs), psychosis (at high doses or in vulnerable individuals), abuse/dependence
- Representative agents
- Methylphenidate (Ritalin, Concerta, Daytrana). Amphetamines (Adderall = mixed salts, dextroamphetamine, lisdexamfetamine).
Black box: Schedule II controlled substances with high abuse potential and dependence. Cardiovascular events in patients with structural heart disease.
Highly effective for ADHD — large effect sizes. Choice between methylphenidate and amphetamine often empirical; some patients respond better to one class than the other. Long-acting formulations preferred for adherence and abuse reduction. Cardiovascular screening before initiation; BP monitoring during treatment.
Two families dominate the class: methylphenidate and amphetamine. Both elevate dopamine and norepinephrine in the prefrontal cortex; both produce the clinical effect of improved attention, working memory, and behavioral inhibition. The mechanisms differ in detail. Methylphenidate blocks the dopamine and norepinephrine transporters — pure reuptake inhibition. Amphetamine blocks the same transporters AND directly releases dopamine and norepinephrine from presynaptic vesicles via VMAT2 reversal. Different mechanisms, similar clinical results — but roughly 30 percent of patients respond better to one class than the other, so trying both classes is reasonable in non-responders.
Stimulants treat ADHD by raising catecholamine signaling in prefrontal circuits — the therapeutic effect and the side-effect profile both flow from that single action.
Mechanism note: Stimulants are the most effective ADHD treatment because they directly strengthen prefrontal catecholamine signaling — the cardiovascular, appetite, sleep, and abuse-liability effects are the same mechanism reaching other sites.
The PFC normalization is the conceptual frame. In ADHD, prefrontal dopamine and norepinephrine signaling is insufficient. Stimulants restore the signal. The "right amount" of monoamine is critical — too little impairs PFC function (the ADHD state), too much also impairs it (the overstimulated state). Stimulants in therapeutic doses move PFC into the optimal range.
Stimulants are Schedule II controlled substances. The DEA scheduling reflects abuse potential, which is real — particularly with IR formulations that produce rapid plasma peaks. Long-acting formulations reduce abuse risk substantially because the slow onset is less reinforcing. Counsel about diversion, secure storage, and PDMP review. The patient with ADHD is at increased risk of substance use disorder, but treatment with stimulants for ADHD does not increase that risk — and may reduce it. The trial data are clear.
Cardiovascular screening before initiation: brief history, family history of sudden cardiac death, BP, HR. ECG if structural heart disease suspected or family history concerning. Annual BP/HR monitoring during treatment. Sympathomimetic effects raise BP and HR modestly; in patients without cardiac disease, this is a manageable side effect. In patients with significant cardiac disease, careful risk-benefit weighting is needed.
For the patient with ADHD whose function is impaired, stimulants are first-line.